FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
JPMorgan analyst Eric Joseph raised the price target on Revolution (NASDAQ: RVMD) to $55.00 (from $42.00) while maintaining a Overweight rating.
The analyst comments "Revisiting our model on the heels of updated phase 1 results for RMC-6236 in 2L+ PDAC, were establishing a Dec-25 price target of $55 (vs prior Dec-24 PT of $42). Key changes to our model include accelerated launch timing (2028 vs 2029 prior) based upon guided... More
BofA Securities analyst Alec Stranahan raised the price target on Revolution (NASDAQ: RVMD) to $55.00 (from $48.00) while maintaining a Buy rating.
The analyst comments "RVMD shares were up (+5.5%, NBI: flat) on the back of what we would characterize as a best-case readout for RMC-6236... More
Stifel analyst Ben Burnett raised the price target on Revolution (NASDAQ: RVMD) to $57.00 (from $43.00) while maintaining a Buy rating.
The analyst comments "We are reiterating our Buy rating and increasing our TP to $57/share following RMC-6236 (RAS-multi) monotherapy results in PDAC which... More
Piper Sandler analyst Joseph Catanzaro raised the price target on Revolution (NASDAQ: RVMD) to $57.00 (from $43.00) while maintaining a Overweight rating.... More
Revolution Medicines (NASDAQ: RVMD) disclosed:
Item7.01 Regulation FD Disclosure.
On July 15, 2024, Revolution Medicines, Inc. (the Company) informed investors that it expects its net loss for the year ended December 31, 2024 to be between $560 million and $600 million, which includes estimated... More
Barclays analyst Peter Lawson initiates coverage on Revolution (NASDAQ: RVMD) with a Overweight rating and a price target of $52.00.
The analyst comments: "We are initiating on Revolution Medicines (RVMD) with an OW rating ahead of two value-inflecting data readouts in 2H24. We are... More
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the publication of a peer-reviewed research paper in Cancer Discovery. The scientific paper demonstrates that the RAS(ON) multi-selective inhibitor RMC-7977 (a preclinical tool compound representative of the investigational drug candidate RMC-6236) exhibited robust and durable anti-tumor activity in multiple preclinical models of KRAS-mutated NSCLC. The data show this activity was further enhanced in the doublet combination with a RAS(ON) G12C-selective inhibitor RMC-4998 (a preclinical tool compound representative of the... More
